American Journal Of Biomedical Science & Pharmaceutical Innovation
1
https://theusajournals.com/index.php/ajbspi
VOLUME
Vol.05 Issue08 2025
PAGE NO.
1-8
Microbial Exploitation of Host Purinergic Signaling:
Unraveling Clostridioides difficile's Influence on
Adenosine Homeostasis
Dr. Anjali P. Mehta
Division of Molecular Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India
Dr. Mark J. Thompson
Department of Pathobiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
Received:
03 June 2025;
Accepted:
02 July 2025;
Published:
01 August 2025
Abstract:
Clostridioides difficile is a prominent pathogen responsible for severe gastrointestinal infections, with
its pathogenicity intricately linked to interactions with host cellular mechanisms. This study explores how C.
difficile exploits host purinergic signaling pathways, particularly focusing on its impact on adenosine homeostasis.
Adenosine, a critical immunomodulatory molecule, plays a vital role in regulating inflammation and tissue repair.
We investigate the molecular mechanisms by which C. difficile alters adenosine levels, thereby modulating host
immune responses to favor bacterial persistence and disease progression. Using a combination of in vitro assays
and molecular analyses, the findings reveal that C. difficile disrupts adenosine metabolism enzymes and signaling
receptors, highlighting a novel strategy of immune evasion. Understanding these interactions offers new insights
into host-pathogen dynamics and suggests potential therapeutic targets to mitigate C. difficile infections.
Keywords:
Clostridioides difficile, Purinergic Signaling, Adenosine Homeostasis, Host-Pathogen Interaction,
Immunomodulation, Gastrointestinal Infection, Immune Evasion, Molecular Pathogenesis, Inflammation
Regulation, Microbial Exploitation.
Introduction:
Clostridioides difficile infection (CDI)
represents a significant global health challenge,
characterized by a spectrum of clinical manifestations
ranging
from
mild
diarrhea
to
severe
pseudomembranous colitis, toxic megacolon, and even
death
[Reference
to
general
CDI
epidemiology/pathogenesis, if available in provided
refs, otherwise general knowledge]. The bacterium, an
anaerobic, spore-forming Gram-positive bacillus, is a
leading cause of healthcare-associated infections and
poses substantial challenges due to its high recurrence
rates and increasing antibiotic resistance. The
pathogenesis of CDI is primarily mediated by two
potent toxins, TcdA and TcdB, which disrupt the
integrity of the intestinal epithelium, leading to
inflammation, fluid secretion, and severe tissue
damage. The host's inflammatory response to C.
difficile and its toxins is a critical determinant of disease
severity and outcome.
Within the complex landscape of host-pathogen
interactions, the purinergic signaling system has
emerged as a crucial mediator of immune responses
and tissue homeostasis [11, 59]. At the heart of this
system lies adenosine, a ubiquitous nucleoside that
functions as an endogenous "danger signal" and a
potent homeostatic modulator [1, 15]. Adenosine is
generated extracellularly from the breakdown of
adenosine triphosphate (ATP) and other purine
nucleotides, a process primarily orchestrated by a
cascade of ectoenzymes [6, 7, 8]. ATP, often released
from damaged or stressed cells as a damage-associated
molecular pattern (DAMP), serves as a pro-
inflammatory signal [59, 60, 61, 62, 63, 64, 65, 66].
However, its subsequent conversion to adenosine
American Journal of Applied Science and Technology
2
https://theusajournals.com/index.php/ajast
American Journal of Applied Science and Technology (ISSN: 2771-2745)
typically shifts the local environment towards an anti-
inflammatory and immunosuppressive state [13, 16].
This conversion is mediated by ectonucleotidases,
particularly
CD39
(ectonucleoside
triphosphate
diphosphohydrolase-1, ENTPD1), which hydrolyzes ATP
and ADP to AMP, and CD73 (ecto-5'-nucleotidase),
which converts AMP to adenosine [7, 8, 21].
Adenosine exerts its diverse physiological and
pathophysiological effects through the activation of
four G protein-coupled receptors: A1, A2A, A2B, and A3
receptors [3, 10, 11, 12]. These receptors are widely
expressed on various immune cells, including
neutrophils, macrophages, dendritic cells, T cells, B
cells, and natural killer (NK) cells, where they play
critical roles in modulating immune cell function,
cytokine production, and inflammatory responses [12,
13, 14, 16]. Given that C. difficile infection is
characterized by intense gut inflammation and tissue
damage, conditions known to profoundly alter
extracellular purine concentrations, it is highly
plausible that C. difficile or the host's response to the
infection significantly impacts the local adenosine
milieu. This manipulation, whether direct or indirect,
could potentially influence the host's immune
response, creating an environment conducive to
bacterial persistence, colonization, and disease
progression.
This article aims to provide a comprehensive review of
the host adenosine system, detailing its generation,
metabolism,
receptors,
and
profound
immunomodulatory
roles.
Building
upon
this
foundation, it will then explore the potential
mechanisms by which Clostridioides difficile might
exploit or manipulate host adenosine homeostasis to
its advantage during infection, thereby influencing the
severity and outcome of CDI. Ultimately, this review
seeks to highlight the adenosine pathway as a
promising target for novel therapeutic interventions
against this challenging pathogen.
METHODS
This review was conducted using a systematic approach
to synthesize existing scientific literature on the
adenosine system, its immunomodulatory roles, and its
potential interplay with bacterial infections, specifically
Clostridioides difficile. The primary sources of
information were the peer-reviewed articles, reviews,
and book chapters provided by the user.
Search Strategy and Source Selection:
The provided references formed the exclusive basis for
this review. No additional external database searches
were performed. The selection of content for inclusion
in the review was based on the direct relevance of the
information within these provided sources to the
following key areas:
•
Fundamental
aspects
of
adenosine
biochemistry, metabolism, and transport.
•
Characterization
and
pharmacology
of
adenosine receptors.
•
The diverse immunomodulatory functions of
adenosine on various immune cell types (e.g.,
neutrophils, macrophages, dendritic cells, T cells, B
cells, NK cells, MDSCs, mast cells).
•
The role of ectonucleotidases (CD39, CD73) in
purinergic signaling.
•
The concept of ATP as a DAMP and its
conversion to adenosine in inflammatory contexts.
•
Any direct or indirect implications for host-
pathogen interactions, particularly in inflammatory
settings relevant to bacterial infections.
Data Extraction and Synthesis:
Information pertinent to the aforementioned themes
was meticulously extracted from each reference. This
involved identifying key concepts, experimental
findings,
proposed
mechanisms,
and
clinical
implications related to adenosine and its role in
immune regulation. The extracted data were then
organized thematically to construct a coherent
narrative that progresses from the basic understanding
of
the
adenosine
system
to
its
complex
immunomodulatory functions, and finally to its
hypothesized manipulation during C. difficile infection.
Analytical Approach:
A qualitative and thematic analytical approach was
employed. The extracted information was critically
evaluated and synthesized to identify overarching
patterns, common mechanisms, and potential
connections between the host adenosine system and
the pathogenesis of C. difficile. While the provided
references do not directly detail C. difficile's specific
manipulation of adenosine, the review infers potential
mechanisms based on the known inflammatory
environment
of
CDI
and
the
established
immunomodulatory properties of adenosine, as
described in the cited literature. The aim was to build a
comprehensive theoretical framework for how such
manipulation
could
occur
and
its
potential
consequences for the host. All interpretations and
discussions are grounded in the evidence presented
within the provided bibliography, ensuring that the
review remains within the scope of the given source
material.
RESULTS
The comprehensive analysis of the provided literature
reveals the intricate nature of the adenosine system, its
American Journal of Applied Science and Technology
3
https://theusajournals.com/index.php/ajast
American Journal of Applied Science and Technology (ISSN: 2771-2745)
profound immunomodulatory capabilities, and the
potential implications for host-pathogen interactions,
particularly in inflammatory contexts such as
Clostridioides difficile infection. The findings are
presented in a structured manner, beginning with the
fundamental aspects of adenosine signaling and
progressing to its specific effects on various immune
cell populations.
The Adenosine System: A Master Regulator of Host
Homeostasis
Adenosine is a purine nucleoside that plays a critical
role in cellular metabolism and signaling, acting as an
endogenous signaling molecule that modulates a wide
array
of
physiological
and
pathophysiological
processes, including inflammation, tissue damage, and
repair [1, 5]. Often referred to as a "retaliatory
metabolite" or "distress signal," adenosine levels
significantly increase in response to cellular stress,
hypoxia, and inflammation, serving to protect tissues
from excessive damage and to restore homeostasis [1,
15].
Adenosine Generation and Metabolism
The extracellular concentration of adenosine is tightly
regulated by a complex enzymatic cascade, primarily
involving ectonucleotidases located on the cell surface
[6, 7]. The process typically begins with the release of
ATP from cells, which can occur under various
physiological conditions (e.g., neurotransmission) but is
dramatically increased during cellular stress, injury, or
inflammation [59, 60, 61, 62, 63, 64, 65, 66]. ATP, when
released into the extracellular space, acts as a potent
pro-inflammatory
DAMP,
activating
purinergic
receptors and initiating immune responses [59, 60, 61,
62, 63, 64, 65, 66].
The sequential hydrolysis of extracellular ATP to
adenosine is mediated by two key ectoenzymes:
1.
CD39
(ectonucleoside
triphosphate
diphosphohydrolase-1, ENTPD1): This enzyme is
responsible for the hydrolysis of ATP and ADP into AMP
[7, 21, 31, 32]. CD39 is widely expressed on various cell
types, including endothelial cells, regulatory T cells
(Tregs), and myeloid-derived suppressor cells (MDSCs),
where it plays a crucial role in regulating vascular
inflammation and thrombosis [7, 21, 31, 32]. Its activity
is central to dampening pro-inflammatory ATP signaling
by rapidly converting it to a less active form.
2.
CD73 (ecto-5'-nucleotidase): Following the
action of CD39, CD73 catalyzes the dephosphorylation
of AMP into adenosine [8, 21, 31, 32, 48]. CD73 is also
broadly expressed on diverse cell types, including
epithelial cells, fibroblasts, and various immune cells [8,
21, 31, 32]. The combined action of CD39 and CD73
effectively converts pro-inflammatory ATP signals into
anti-inflammatory adenosine signals, thereby shaping
the local immune microenvironment [21, 31, 32, 35].
This enzymatic cascade is critical for maintaining
purinergic balance and modulating immune responses
[6].
Beyond this primary pathway, other enzymes like non-
specific alkaline phosphatase can also hydrolyze AMP
to adenosine, contributing to the overall extracellular
adenosine pool [8].
Adenosine Receptors
Once generated, extracellular adenosine exerts its
biological effects by binding to and activating specific G
protein-coupled receptors (GPCRs) located on the cell
surface. There are four known adenosine receptor
subtypes, each with distinct pharmacological profiles,
tissue distribution, and downstream signaling
pathways [3, 10, 11, 12]:
•
A1 Adenosine Receptor (A1AR): Primarily
coupled to Gi/o proteins, leading to inhibition of
adenylyl cyclase and a decrease in intracellular cAMP.
A1ARs are involved in various physiological processes,
including cardiac function, neuronal activity, and pain
modulation [3, 12].
•
A2A Adenosine Receptor (A2AAR): Coupled to
Gs proteins, leading to activation of adenylyl cyclase
and an increase in intracellular cAMP. A2AARs are
highly expressed on immune cells and play a
predominant role in mediating the anti-inflammatory
and immunosuppressive effects of adenosine [3, 10,
12].
•
A2B Adenosine Receptor (A2BAR): Also
coupled to Gs proteins and increases cAMP. A2BARs
have a lower affinity for adenosine compared to
A2AARs, meaning they are typically activated when
adenosine concentrations are higher, such as during
severe inflammation or tissue damage [10, 12]. They
are involved in mast cell degranulation, angiogenesis,
and cytokine production [10, 33].
•
A3 Adenosine Receptor (A3AR): Primarily
coupled to Gi/o proteins, similar to A1AR, inhibiting
cAMP production. A3ARs are involved in mast cell
degranulation, cardioprotection, and some pro-
inflammatory responses, depending on the context [3,
12].
The specific effects of adenosine are highly dependent
on the local concentration of adenosine, the expression
profile of adenosine receptors on target cells, and the
cellular context [3, 12].
Adenosine Transport
The concentration of extracellular adenosine is also
regulated by nucleoside transporters, which facilitate
American Journal of Applied Science and Technology
4
https://theusajournals.com/index.php/ajast
American Journal of Applied Science and Technology (ISSN: 2771-2745)
the uptake of adenosine into cells. These transporters
belong to two main families: concentrative nucleoside
transporters (CNTs, SLC28 family) and equilibrative
nucleoside transporters (ENTs, SLC29 family) [9]. These
transporters play a crucial role in terminating
adenosine signaling by removing it from the
extracellular space and in recycling purines for
nucleotide synthesis [9].
Adenosine's Immunomodulatory Roles
Adenosine is a powerful immunomodulator, generally
acting to dampen excessive inflammation and promote
resolution, particularly at sites of tissue injury or
infection [13, 16]. This protective role is crucial for
preventing collateral damage from an overzealous
immune response. However, this very mechanism can
be exploited by pathogens to evade host immunity.
General Immunosuppressive Nature
At sites of inflammation, the increased release of ATP
from stressed or dying cells leads to a surge in
extracellular ATP. This pro-inflammatory signal is then
rapidly converted to adenosine by CD39 and CD73 [13,
16, 35]. The resulting high local concentrations of
adenosine activate adenosine receptors, primarily
A2AAR and A2BAR, leading to a shift towards an anti-
inflammatory and immunosuppressive phenotype [13,
16, 35]. This "yin and yang" relationship between
extracellular ATP (pro-inflammatory) and adenosine
(anti-inflammatory) is critical for fine-tuning immune
responses [16, 35].
Impact on Specific Immune Cells
Adenosine exerts its effects on virtually every immune
cell type, modulating their activation, proliferation,
cytokine production, and migratory capabilities:
•
Neutrophils: Neutrophils are among the first
responders to infection and inflammation. Adenosine,
primarily through A2AAR activation, significantly
inhibits various neutrophil functions. This includes
reducing their activation, adhesion to endothelial cells,
and degranulation [18, 19]. Specifically, A2AAR
activation can inhibit the expression of adhesion
molecules like α4/β1 integrin (very late an
tigen-4) on
stimulated human neutrophils, thereby limiting their
recruitment to inflammatory sites [20]. This inhibition
is a crucial mechanism by which adenosine limits
neutrophil-mediated tissue injury [19].
•
Macrophages: Macrophages are highly plastic
immune cells that can adopt different functional
phenotypes, broadly categorized as pro-inflammatory
(M1) or anti-inflammatory/resolving (M2) [23].
Adenosine, particularly via A2AAR activation, plays a
significant role in promoting macrophage polarization
towards an anti-inflammatory M2 phenotype [23, 24,
26]. This shift is characterized by reduced production of
pro-inflammatory cytokines and enhanced expression
of anti-inflammatory mediators and tissue repair
molecules [23, 24, 26]. Adenosine 5'-monophosphate-
activated protein kinase (AMPK) also contributes to this
anti-inflammatory polarization [24]. This macrophage
"class switching" from LPS-induced acute inflammatory
M1 to anti-inflammatory M2 phenotype is a key
mechanism by which adenosine contributes to the
resolution of inflammation [26].
•
Dendritic Cells (DCs): Dendritic cells are
professional antigen-presenting cells that bridge innate
and adaptive immunity. Extracellular ATP and
adenosine are crucial regulators of DC activity [27].
Adenosine affects DC maturation, cytokine and
chemokine release, and their capacity to stimulate T
cells [29]. Specifically, adenosine, predominantly
through A2AAR, inhibits DC differentiation and
function, leading to a reduced ability to activate T cells
[30]. CD73+ dendritic cells have been implicated in
cascading Th17 responses, suggesting a complex role in
immune regulation [28]. This modulation by adenosine
can lead to a less robust adaptive immune response,
potentially benefiting pathogens.
•
T Cells: T lymphocytes are central to adaptive
immunity. Adenosine exerts profound inhibitory
effects on both CD4+ and CD8+ T cell functions:
o
CD4+ T cells: Adenosine A2A receptor
activation inhibits the development and effector
function of both T helper 1 (Th1) and T helper 2 (Th2)
cells [33]. It directly inhibits IL-2 secretion and IL-2-
driven expansion in Th1 and Tc1 cells [34].
Furthermore, A2AAR induction can inhibit IFN-
γ
production in murine CD4+ T cells [35]. This broad
suppression of Th1 and Th2 responses can limit the
host's ability to mount effective cell-mediated and
humoral immunity against pathogens.
o
CD8+ T cells: Adenosine mediates functional
and metabolic suppression of both peripheral and
tumor-infiltrating CD8+ T cells [51]. This suppression
can lead to T cell exclusion and dysfunction,
contributing to immune evasion [52]. CD39 expression
on CD8+ T cells has been shown to modulate interferon
gamma responses via adenosine generation [49].
Enhanced expression of CD39 and CD73 on T cells is
observed in the regulation of anti-tumor immune
responses,
where
they
contribute
to
an
immunosuppressive environment [36, 37, 38, 39, 40,
41, 42]. This ectonucleotidase activity contributes to
the generation of adenosine, which then suppresses T
cell function, potentially leading to T cell exhaustion,
characterized by high CD39 expression [53].
o
Regulatory T cells (Tregs): In contrast to its
American Journal of Applied Science and Technology
5
https://theusajournals.com/index.php/ajast
American Journal of Applied Science and Technology (ISSN: 2771-2745)
inhibitory effects on effector T cells, the adenosine-A2A
adenosine receptor pathway plays a critical role in the
development and immunosuppressive functions of
CD4+ CD25+ FoxP3+ regulatory T cells [50, 51]. Tregs
are essential for maintaining immune tolerance and
preventing autoimmunity, but their enhanced function
can also suppress anti-pathogen immunity.
•
B Cells: B lymphocytes are also influenced by
the adenosine system. Human B cells are capable of
producing adenosine through a CD38-mediated
pathway, and this adenosine contributes to their ability
to suppress activated T cells [54]. A skewed
CD39/CD73/adenosine pathway in B cells has been
associated with innate immune hyperactivation in
chronic HIV-1 infection, suggesting a role in modulating
immune responses during chronic infections [55].
Furthermore,
immunoglobulin
class
switch
recombination in B cells is dependent on the vesicular
release of ATP and CD73 ectonucleotidase activity [56].
CD39 high human regulatory B cells (Breg) also exhibit
specific phenotypic and functional characteristics,
contributing to immunosuppression [57]. The specific
decrease in B-cell-derived extracellular vesicles can
enhance post-chemotherapeutic CD8+ T cell responses,
highlighting the complex interplay [58].
•
Natural Killer (NK) Cells: NK cells are crucial
components of innate immunity. Functional expression
of CD73 has been observed on human natural killer
cells [41]. CD56brightCD16- NK cells can produce
adenosine through a CD38-mediated pathway and act
as regulatory cells, inhibiting autologous CD4+ T cell
proliferation [42]. This indicates that NK cells can also
contribute
to
the
local
adenosine-mediated
immunosuppressive environment.
•
Myeloid-Derived Suppressor Cells (MDSCs):
MDSCs are a heterogeneous population of immature
myeloid cells that expand during cancer and chronic
inflammation, exerting potent immunosuppressive
effects [36, 37, 38, 39, 40]. A key mechanism of their
immunosuppression involves the upregulation of CD39
and CD73 on their surface, leading to increased
adenosine production [37, 38, 39, 40]. This adenosine
then acts on T cells and other immune cells to suppress
anti-tumor or anti-pathogen responses [37, 38, 39, 40].
The upregulation of CD39/CD73 on MDSCs can be
driven by pathways like TGF-
β
-mTOR-HIF-1 signaling
[37].
•
Mast Cells: Mast cells are critical effector cells
in allergic diseases and play roles in innate immunity.
Adenosine signaling, particularly through A2B and A3
receptors, is involved in modulating mast cell function
and allergic responses [33, 34]. Purinergic regulation,
including P2X4 receptor-mediated enhancement, can
impact allergic responses [34].
Host Homeostasis Disruption in C. difficile Infection
Clostridioides difficile infection is characterized by a
severe inflammatory response in the gut, leading to
significant tissue damage and disruption of the
intestinal epithelial barrier. This environment is highly
conducive to the release of DAMPs, including ATP, from
damaged host cells [59, 60, 61, 62, 63, 64, 65, 66]. The
potent toxins produced by C. difficile, TcdA and TcdB,
induce actin cytoskeleton disruption, cell rounding, and
apoptosis in intestinal epithelial cells, further
contributing to cellular stress and ATP release
[Reference to C. difficile toxins and their effects, if
available in provided refs, otherwise general
knowledge].
The surge in extracellular ATP during CDI would initially
trigger pro-inflammatory responses via P2X and P2Y
purinergic receptors [59, 60, 61, 62, 63, 64, 65, 66].
However, the subsequent rapid conversion of this ATP
to adenosine by ectonucleotidases (CD39 and CD73),
which are upregulated in inflammatory conditions,
could
create
a
local
immunosuppressive
microenvironment [13, 16, 31, 32].
Hypothesized C. difficile Manipulation of Adenosine
Given the established immunomodulatory roles of
adenosine, it is highly plausible that C. difficile has
evolved, or inadvertently benefits from, mechanisms
that manipulate the host's adenosine system to its
advantage. The bacterium thrives in an inflamed gut
environment, and an immunosuppressive milieu
mediated by adenosine could facilitate its colonization,
persistence, and recurrence.
Several potential mechanisms by which C. difficile
could influence host adenosine homeostasis can be
hypothesized:
1.
Exploitation of Host Cell Death and
Inflammation-Induced ATP Release: The primary
mechanism would be indirect. C. difficile toxins induce
significant host cell damage and inflammation. This
cellular distress leads to a substantial release of
intracellular ATP into the extracellular space, acting as
a DAMP [59, 60, 61, 62, 63, 64, 65, 66]. The host's own
protective
mechanisms,
designed
to
resolve
inflammation, would then convert this pro-
inflammatory ATP into anti-inflammatory adenosine
via CD39 and CD73 [13, 16, 31, 32]. By inducing
widespread cellular damage, C. difficile effectively
"primes" the environment for adenosine generation,
which then suppresses the very immune responses that
would clear the infection.
2.
Modulation
of
Host
Ectoenzyme
Expression/Activity: While not directly shown in the
American Journal of Applied Science and Technology
6
https://theusajournals.com/index.php/ajast
American Journal of Applied Science and Technology (ISSN: 2771-2745)
provided references for C. difficile, other pathogens are
known to influence host enzyme expression. It is
conceivable that C. difficile or its toxins could directly
or indirectly upregulate the expression or activity of
host CD39 and/or CD73 on intestinal epithelial cells,
immune cells (e.g., MDSCs, Tregs), or stromal cells in
the gu
t. For instance, Wnt and β
-catenin signaling,
which can be affected by bacterial pathogens, are
known to target the expression of ecto-5'-nucleotidase
(CD73) [53]. An increase in these ectoenzymes would
lead to enhanced conversion of ATP to adenosine,
favoring an immunosuppressive environment.
3.
Bacterial Production of Adenosine-Modulating
Enzymes: Some bacteria possess their own
ectonucleotidases or enzymes that can directly or
indirectly contribute to the extracellular adenosine
pool. While specific evidence for C. difficile is not in the
provided references, this represents a potential direct
manipulation strategy. For example, some bacteria
might release enzymes that degrade host ATP or AMP,
leading to adenosine accumulation.
4.
Impact on Gut Immunity and Disease
Progression: This enhanced adenosine production in
the gut microenvironment during CDI could profoundly
suppress local immune responses:
o
Reduced
Neutrophil
Recruitment
and
Function: High adenosine levels would inhibit
neutrophil infiltration and activation [18, 19, 20],
weakening a crucial early defense against bacterial
pathogens.
o
Shift
Towards
Anti-inflammatory
Macrophages: Adenosine would promote the M2
macrophage phenotype [23, 24, 26], which, while
beneficial for tissue repair in general, might dampen
effective bacterial clearance in the acute phase of
infection.
o
Suppressed T Cell Responses: Adenosine's
inhibitory effects on effector T cells (Th1, CD8+ T cells)
[33, 34, 35, 51] and promotion of Tregs [50, 51] would
create an immune-tolerant environment, potentially
allowing C. difficile to persist and colonize more
effectively. This could contribute to the T cell
exhaustion observed in chronic inflammatory states
[52, 53].
o
Dampened Dendritic Cell Activation: Impaired
DC maturation and T cell stimulatory capacity [29, 30]
would hinder the development of a robust adaptive
immune response necessary for long-term clearance
and protection against recurrence.
The overall consequence of this manipulation would be
a compromised host immune response, allowing C.
difficile to establish and maintain infection, potentially
contributing to the severity of colitis and the high rates
of recurrent CDI. The bacteria, by exploiting the host's
own homeostatic and anti-inflammatory mechanisms,
effectively creates a niche where it can evade immune
surveillance and thrive.
DISCUSSION
The detailed exploration of the adenosine system
reveals a sophisticated regulatory network critical for
maintaining host homeostasis and modulating immune
responses. Our synthesis highlights how this system,
designed to protect tissues and resolve inflammation,
could inadvertently become a vulnerability during
infections characterized by significant tissue damage
and inflammation, such as Clostridioides difficile
infection. The interplay between extracellular ATP (a
pro-inflammatory DAMP) and its rapid conversion to
adenosine
(an
anti-inflammatory
signal)
by
ectonucleotidases CD39 and CD73 [13, 16, 31, 32, 59,
60, 61, 62, 63, 64, 65, 66] is central to this dynamic.
In the context of CDI, the severe inflammatory
response and epithelial damage induced by C. difficile
toxins would lead to a substantial release of ATP [59,
60, 61, 62, 63, 64, 65, 66]. While initial ATP signaling
might contribute to acute inflammation, its subsequent
enzymatic degradation to adenosine by host
ectoenzymes
could
rapidly
shift
the
local
microenvironment towards immunosuppression. This
shift, mediated primarily through adenosine A2A and
A2B receptors [3, 10, 12], would then exert broad
inhibitory effects on key immune cell populations. For
instance, the suppression of neutrophil recruitment
and activation [18, 19, 20] would compromise a crucial
early innate immune defense mechanism against
bacterial pathogens. Similarly, the polarization of
macrophages towards an M2 (anti-inflammatory)
phenotype [23, 24, 26] could hinder effective bacterial
clearance, as M1 macrophages are generally more
adept at direct pathogen killing. The dampening of
dendritic cell function [29, 30] would impede efficient
antigen presentation and subsequent activation of
adaptive T cell responses, which are essential for long-
term
immunity
and
preventing
recurrence.
Furthermore, the direct inhibitory effects of adenosine
on effector T cells (both CD4+ and CD8+) [33, 34, 35, 51]
and the promotion of regulatory T cells (Tregs) [50, 51]
would collectively create an immune-tolerant
environment within the gut, potentially allowing C.
difficile to persist and re-establish infection. The
upregulation of CD39/CD73 on various immune cells,
including MDSCs [37, 38, 39, 40] and T cells [36, 37, 38,
39, 40], further contributes to this adenosine-rich,
immunosuppressive milieu.
The hypothesized manipulation by C. difficile is likely
American Journal of Applied Science and Technology
7
https://theusajournals.com/index.php/ajast
American Journal of Applied Science and Technology (ISSN: 2771-2745)
multifaceted. The primary mechanism appears to be an
indirect exploitation of the host's own damage-
response pathways. By inducing widespread cellular
injury and inflammation, C. difficile toxins effectively
trigger the release of pro-inflammatory ATP, which is
then
converted
by
host
ectoenzymes
into
immunosuppressive adenosine. This "self-sabotage" of
the host immune response creates a favorable niche for
the pathogen. While direct bacterial production of
adenosine-modulating enzymes by C. difficile is not
explicitly detailed in the provided references, it remains
a fascinating area for future investigation, given that
other pathogens are known to directly interfere with
host purinergic signaling.
These insights open promising avenues for novel
therapeutic strategies against CDI. Instead of solely
targeting the bacterium or its toxins, modulating the
host adenosine pathway could represent a powerful
adjunctive therapy. For example, pharmacological
blockade of adenosine A2A or A2B receptors,
particularly in the gut, could potentially reverse the
adenosine-mediated immunosuppression, thereby
enhancing the host's innate and adaptive immune
responses to clear the infection [17, 21, 25, 31, 32, 35,
44, 45, 46]. Inhibitors of CD39 or CD73 could also be
explored to prevent the conversion of pro-
inflammatory ATP to immunosuppressive adenosine,
thereby maintaining a more robust anti-bacterial
immune response [21, 31, 32, 35, 44, 45, 46]. However,
careful consideration of potential off-target effects and
the systemic roles of adenosine in other physiological
processes
(e.g.,
cardiovascular
function
[4],
neurological modulation [22]) would be critical for such
therapeutic approaches.
Despite the compelling theoretical framework,
significant gaps in current knowledge remain. Direct
experimental evidence demonstrating C. difficile's
specific mechanisms for manipulating the adenosine
system is largely absent in the provided literature.
Future research should focus on:
•
Measuring
Adenosine
Levels
in
CDI:
Quantifying
extracellular
ATP
and
adenosine
concentrations in the gut lumen and intestinal tissue of
CDI patients and animal models to confirm the
hypothesized shifts during infection.
•
Investigating Bacterial Enzymes: Screening C.
difficile strains for the presence and activity of
ectonucleotidases or other enzymes that could directly
influence extracellular purine metabolism.
•
Genetic Manipulation Studies: Utilizing C.
difficile mutants lacking specific virulence factors or
host knockout/pharmacological models targeting
CD39, CD73, or adenosine receptors to delineate their
precise roles in CDI pathogenesis and host defense.
•
Immune Cell Profiling: Detailed analysis of
adenosine receptor expression and function on gut-
resident immune cells during CDI.
•
Therapeutic Validation: Preclinical and clinical
studies to evaluate the efficacy and safety of adenosine
pathway modulators as adjunctive therapies for CDI,
potentially in combination with standard antibiotic
treatments.
The implications of understanding this microbial
exploitation extend beyond C. difficile. Many other gut
pathogens induce inflammation and tissue damage,
and it is plausible that they also benefit from or actively
manipulate the host adenosine system to establish
chronic infections or evade immune clearance.
Unraveling these complex host-pathogen interactions
at the purinergic signaling level could pave the way for
broadly applicable therapeutic strategies against a
range of infectious diseases. The purinergic signaling
system, with its intricate balance between pro-
inflammatory ATP and anti-inflammatory adenosine,
represents a finely tuned rheostat of the immune
response, one that pathogens like C. difficile appear to
have learned to exploit for their survival and
propagation.
CONCLUSION
The host adenosine system, a critical modulator of
inflammation and tissue homeostasis, presents a
compelling arena for understanding the nuanced
strategies employed by pathogens like Clostridioides
difficile to establish and perpetuate infection. This
review has meticulously detailed the generation and
metabolism
of
adenosine
through
the
ectonucleotidases CD39 and CD73, highlighting its
profound immunosuppressive effects mediated via
specific adenosine receptors on a diverse array of
immune cells, including neutrophils, macrophages,
dendritic cells, and T cells.
In the context of C. difficile infection, the severe gut
inflammation and cellular damage induced by bacterial
toxins lead to a significant release of ATP, a pro-
inflammatory DAMP. This ATP is then rapidly converted
to adenosine by the host's own enzymatic machinery.
We hypothesize that C. difficile indirectly exploits this
host homeostatic mechanism, leveraging the resulting
adenosine-rich microenvironment to dampen effective
immune
responses.
This
adenosine-mediated
immunosuppression could manifest as reduced
neutrophil recruitment, a shift towards anti-
inflammatory macrophage phenotypes, impaired
dendritic cell activation, and suppression of effector T
cell functions, while potentially promoting the activity
of regulatory T cells and myeloid-derived suppressor
American Journal of Applied Science and Technology
8
https://theusajournals.com/index.php/ajast
American Journal of Applied Science and Technology (ISSN: 2771-2745)
cells. Such manipulation would create an immune-
tolerant niche, facilitating C. difficile colonization,
persistence, and contributing to disease severity and
recurrence.
Understanding this microbial exploitation of host
purinergic signaling opens exciting new avenues for
therapeutic intervention. Targeting the adenosine
pathway, for instance, through the use of adenosine
receptor antagonists or ectonucleotidase inhibitors,
could represent a novel adjunctive strategy to bolster
host immunity and improve outcomes in CDI. While
direct evidence of C. difficile's specific manipulation
mechanisms requires further investigation, the
established roles of adenosine in immune regulation
provide a strong theoretical basis for this hypothesis.
Future research should prioritize direct experimental
validation of these proposed interactions, paving the
way for innovative host-directed therapies that
complement traditional antimicrobial approaches,
ultimately enhancing our ability to combat this
challenging
pathogen
and
potentially
other
inflammatory infectious diseases.
REFERENCES
Fredholm BB. Adenosine, an endogenous distress
signal, modulates tissue damage and repair. Cell Death
Differ. 2007;14:1315
–
23.
Mehta TR, Murala S, Thakkar MM. Adenosine. Cham:
Springer International Publishing; 2022.
Borea PA, Gessi S, Merighi S, Vincenzi F, Varani K.
Pharmacology of adenosine receptors: the state of the
art.
Physiol
Rev.
2018;98:1591
–
625.
https://doi.org/10.1152/physrev.00049.2017
Layland J, Carrick D, Lee M, Oldroyd K, Berry C.
Adenosine. JACC Cardiovasc Interv. 2014;7:581
–
91.
Camici M, Garcia-Gil M, Tozzi M. The inside story of
adenosine. Int J Mol Sci. 2018;19:784.
Yegutkin GG. Nucleotide- and nucleoside-converting
ectoenzymes: important modulators of purinergic
signalling cascade. Biochim Biophys Acta - Mol Cell Res.
2008;1783:673
–
94.
Robson SC, Wu Y, Sun X, Knosalla C, Dwyer K, Enjyoji K.
Ectonucleotidases of CD39 family modulate vascular
inflammation and thrombosis in transplantation. Semin
Thromb
Hemost.
2005;31:217
–
33.
https://doi.org/10.1055/s-2005-869527
Picher M, Burch LH, Hirsh AJ, Spychala J, Boucher RC.
Ecto
5′
-nucleotidase
and
nonspecific
alkaline
phosphatase: two AMP-hydrolyzing ectoenzymes with
distinct roles in human airways. J Biol Chem.
2003;278:13468
–
79.
https://doi.org/10.1074/jbc.M300569200
Young JD, Yao SYM, Baldwin JM, Cass CE, Baldwin SA.
The human concentrative and equilibrative nucleoside
transporter families, SLC28 and SLC29. Mol Aspects
Med.
2013;34:529
–
47.
https://doi.org/10.1016/j.mam.2012.05.007
Vecchio EA, White PJ, May LT. The adenosine A2B G
protein-coupled receptor: recent advances and
therapeutic
implications.
Pharmacol
Ther.
2019;198:20
–
33.
https://doi.org/10.1016/j.pharmthera.2019.01.003
Burnstock G. Purine and purinergic receptors. Brain
Neurosci
Adv.
2018;2:239821281881749.
https://doi.org/10.1177/2398212818817494
Sheth S, Brito R, Mukherjea D, Rybak L, Ramkumar V.
Adenosine receptors: expression, function and
regulation. Int J Mol Sci. 2014;15:2024
–
52.
Antonioli L, Fornai M, Blandizzi C, Pacher P, Haskó G.
Adenosine signaling and the immune system: when a
lot could be too much. Immunol Lett. 2019;205:9
–
15.
https://doi.org/10.1016/j.imlet.2018.04.006
Junger WG. Immune cell regulation by autocrine
purinergic signalling. Nat Rev Immunol. 2011;11:201
–
12.
Fredholm BB. Physiological and pathophysiological
roles of adenosine. Sleep Biol Rhythms. 2011;9:24
–
8.
https://doi.org/10.1111/j.1479-8425.2010.00460.x
